Bristol-Myers Squibb to Sell its Manufacturing Facility to Catalent in Anagni, Italy

Shots:

• Catalent to purchase BMS’ oral solid, biologics, and sterile product manufacturing and packaging facility and will continue to manufacture BMS’s current product portfolio at the site, providing facilities in Europe, Belgium & NA
• Bristol-Myers Squibb will maintain its strategic presence in Italy with the ongoing development and commercialization of new therapies. The transaction is expected to close in H2’19
• BMS’ Anagni facility consist of floor space of ~ 19,300 m² on a site of 34 hectares, manufacturing & packaging therapies across multiple therapy areas including CV & oncology as well as non-penicillin-based antibiotics, antivirals, analgesics as injectables and biologics

Click here to read full press release/ article | Ref: BMS | Image: Wall Street Journal